- Home
- ROMA vs WHWK Comparison
ROMA vs WHWK Comparison
Compare ROMA & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROMA | WHWK |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.5M | 95.2M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | ROMA | WHWK |
|---|---|---|
| Price | $1.33 | $2.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 10.5K | ★ 136.4K |
| Earning Date | 12-26-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,640,101.00 | ★ $14,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 59.60 | N/A |
| 52 Week Low | $0.58 | $1.39 |
| 52 Week High | $4.66 | $3.77 |
Technical Indicators
Market Signals| Indicator | ROMA | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 19.70 | 58.29 |
| Support Level | $1.16 | $2.36 |
| Resistance Level | $1.75 | $2.77 |
| Average True Range (ATR) | 0.34 | 0.16 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 13.29 | 61.22 |
Price Performance
Historical ComparisonAbout ROMA Roma Green Finance Limited
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.